Newsroom Articles

Our new digital children’s book, Alexander’s Not-So-Secret Diary, brings this belief to life through the experiences of nine-year-old Alexander, who is living with Alexander disease (AxD), an ultra-rare, progressive and often fatal neurological disorder that affects approximately 1 in 1 to 3 million people worldwide.

More than three million people in the United States are living with very high triglycerides 500 mg/dL or higher, also known as severe hypertriglyceridemia (sHTG), yet many are left to navigate a complex care journey largely on their own. With support from Ionis, the Hidden in Plain Sight white paper was developed in partnership with the National Triglyceride Alliance, leading clinicians, patient advocates, people living with very high triglycerides and their care partners to examine the gap between recognition and care and the collective action required to close it.

Ionis has been recognized as Science’s #1 Top Employer for 2026. In only our second year of eligibility, this honor highlights our industry-leading innovation, talented employees and strong values-based culture.

RNA-targeted medicines work differently. Learn how they interact with RNA to address disease earlier than traditional approaches – and why it matters.

For David and his mother, Melissa, moments of joy are an important part of life with Alexander disease (AxD), an ultra-rare, progressive and often fatal neurological disorder that affects approximately 1 in 1 to 3 million people worldwide.

Beth’s recognition reflects more than 25 years of leadership at Ionis. As a member of the executive leadership team, she has helped guide the company’s transformation from an organization focused primarily on research and early development into a fully integrated commercial-stage biotech.

When triglyceride levels reach 500 mg/dL or higher, the risks of serious complications like acute pancreatitis and atherosclerotic cardiovascular disease can increase. Watch as people living with sHTG share their experiences and reveal the often-misunderstood realities of living with this serious condition.

Advances in science and treatment are changing how severe hypertriglyceridemia (sHTG) is identified and managed. Here are four trends helping shape the future of care.

Ionis has been recognized as one of the San Diego Business Journal's Best Places to Work for the third consecutive year. This year, Ionis ranked #3 in the Large Company category, climbing three spots from #6 in 2025.

Explore Yajaira's journey with severe hypertriglyceridemia (sHTG), including the risks of high triglycerides, pancreatitis, and the importance of early awareness.

Explore Ionis' 2025 Corporate Responsibility Report — covering RNA-targeted medicine breakthroughs, ESG commitments, employee impact, and sustainability milestones.

March marks Amyloidosis Awareness Month. We sat down with Charles, an 88-year-old retired cardiologist from Massachusetts, who shared what it’s like to diagnose and treat heart disease for decades and then face a diagnosis himself. His experience with transthyretin amyloid cardiomyopathy (ATTR-CM) offers a unique perspective on this underrecognized condition.